PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia

Affiliations

¹ Department of Medicine, Division of Medical Oncology, University of British Columbia, Vancouver, BC V5Z 4E6, Canada. Electronic address: atinker@bccancer.bc.ca.

Comment

Anna V Tinker. Lancet Haematol. 2021 Feb.

. 2021 Feb;8(2):e97-e99.

doi: 10.1016/S2352-3026(20)30375-6. Epub 2020 Dec 18.

¹ Department of Medicine, Division of Medical Oncology, University of British Columbia, Vancouver, BC V5Z 4E6, Canada. Electronic address: atinker@bccancer.bc.ca.

No abstract available

Comment on

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, Moore K, O'Reilly EM, Ray-Coquard I, Alexandre J. Morice PM, et al. Lancet Haematol. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18. Lancet Haematol. 2021. PMID: 33347814